VIENNA — In a phase 2 study, SAR402663 gene therapy for wet age-related macular degeneration showed positive efficacy and safety interim results with a single in-office intravitreal injection.
With a medium dose of SAR402663, there was a 97% reduction in treatment burden, with more than 90% of patients not needing supplemental anti-VEGF injections, Arshad M. Khanani, MD, MA, FASRS, said at the Euretina congress.
Researchers have observed positive functional and anatomic results with the therapy, and the safety profile appears good.
SAR402663 (Sanofi) is an investigational AAV2 gene therapy